• Anne-Marie Dupuy, François Philippart, Yves Péan, Sigismond Lasocki, Pierre-Emmanuel Charles, Martin Chalumeau, Yann-Eric Claessens, Jean-Pierre Quenot, Christele Gras-Le Guen, Stéphanie Ruiz, Charles-Edouard Luyt, Nicolas Roche, Jean-Paul Stahl, Jean-Pierre Bedos, Jérôme Pugin, Rémy Gauzit, Benoit Misset, Christian Brun-Buisson, and Maurice Rapin Institute Biomarkers Group.
• Service de Réanimation médicale, Hôpitaux Universitaires Henri Mondor, AP-HP & Université Paris-Est, 94000 Créteil, France. Christian.brun-buisson@hmn.aphp.fr.
• Ann Intensive Care. 2013 Jan 1;3(1):22.

AbstractIn the context of worldwide increasing antimicrobial resistance, good antimicrobial prescribing in more needed than ever; unfortunately, information available to clinicians often are insufficient to rely on. Biomarkers might provide help for decision-making and improve antibiotic management. The purpose of this expert panel review was to examine currently available literature on the potential role of biomarkers to improve antimicrobial prescribing, by answering three questions: 1) Which are the biomarkers available for this purpose?; 2) What is their potential role in the initiation of antibiotic therapy?; and 3) What is their role in the decision to stop antibiotic therapy? To answer these questions, studies reviewed were limited to recent clinical studies (<15 years), involving a substantial number of patients (>50) and restricted to controlled trials and meta-analyses for answering questions 2 and 3. With regard to the first question concerning routinely available biomarkers, which might be useful for antibiotic management of acute infections, these are currently limited to C-reactive protein (CRP) and procalcitonin (PCT). Other promising biomarkers that may prove useful in the near future but need to undergo more extensive clinical testing include sTREM-1, suPAR, ProADM, and Presepsin. New approaches to biomarkers of infections include point-of-care testing and genomics.

2 keywords...

hide…